Fortress Biotech reports FY23 EPS ($8.47) vs. ($15.97) last year

Reports FY23 revenue $84.51M vs. $75.74M last year. Lindsay A. Rosenwald, M.D., Fortress’ Chairman, President and Chief Executive Officer, said, “In 2023, we built a significant amount of momentum to position our Company to achieve multiple milestones in 2024. We also generated record consolidated net revenues of $84.5 million in 2023, the majority of which came from the sales and milestone payments from our dermatology and rare disease businesses. We are pleased that the U.S. Food and Drug Administration accepted the New Drug Application filing for DFD-29 earlier this month and look forward to the Prescription Drug User Fee Act goal date of November 4, 2024. Across our portfolio, we could receive up to four NDA and Biologics License Application regulatory approvals over the next 18 months, while we continue to advance our 25 development stage programs in 2024.”